Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lncRNA 585189 inhibitor
- Development stage
- Preclinical
- Lead developer
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
lncRNA 585189 inhibitor refers to preclinical therapeutic agents, such as small interfering RNAs (siRNAs) or antisense oligonucleotides, designed to target and silence the long non-coding RNA ENST00000585189.1 (lncRNA 585189). Upregulated in patients with diabetic nephropathy (DN) and high-glucose-induced human podocytes, lncRNA 585189 physically interacts with and destabilizes the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) protein. This destabilization downregulates hnRNP A1, which in turn reduces the stability and expression of Sirtuin 1 (SIRT1) mRNA. By inhibiting lncRNA 585189, these inhibitors restore hnRNP A1 and SIRT1 levels, thereby decreasing reactive oxygen species (ROS) production, rescuing mitochondrial morphology and membrane potential, and preventing podocyte injury. This approach represents a promising preclinical strategy for the treatment of diabetic nephropathy.
- Other names
- ENST00000585189.1 inhibitorENST-00000585189.1 inhibitorENST 00000585189.1 inhibitorlncRNA ENST00000585189.1 inhibitor
Beyond the preview
Go deeper on lncRNA 585189 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lncRNA 585189 inhibitor.